FDA’s Proposed Name Review Pilot Offers Little Reason To Participate

A proposed FDA pilot program that would shift the burden for safety review of proprietary drug names from the agency to industry needs to account for key differences between OTC and Rx products and lacks participation incentives, pharmaceutical researchers say

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet